Illumina (NASDAQ: ILMN) reported Q4 EPS of $0.87, $0.10 better than the analyst estimate of $0.77. Revenue for the quarter came in at $512 million versus the consensus estimate of $503.83 million.

Illumina sees FY2015 EPS of $3.12-$3.18, versus the consensus of $3.20.

"We delivered record fourth quarter and fiscal year 2014 financial results which greatly exceeded our expectations. Our focus on technology innovation, as evidenced by the launch of HiSeq XTM Ten, which enables the $1,000 genome, and the NextSeq® 500, were major contributors to our outperformance,” stated Jay Flatley, CEO. “The recently announced HiSeq X Five, HiSeq® 3000/4000 and NextSeq 550 instruments further enhance the most extensive sequencing portfolio available, and will position us for continued long-term growth as we develop and address the large and nascent market opportunities ahead of us.”

For earnings history and earnings-related data on Illumina (ILMN) click here.